
Angel Perez-Sempere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2488276/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuroimaging in the Evaluation of Patients with Non-Acute Headache. Cephalalgia, 2005, 25, 30-35.	1.8	110
2	Screening Parkinson's disease: A validated questionnaire of high specificity and sensitivity. Movement Disorders, 1995, 10, 643-649.	2.2	74
3	Prevalence of Parkinson's disease in Cantalejo, Spain: A door-to-door survey. Movement Disorders, 2002, 17, 242-249.	2.2	68
4	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Multiple Sclerosis Journal, 2009, 15, 1303-1310.	1.4	57
5	First seizure in adults: a prospective study from the emergency department. Acta Neurologica Scandinavica, 1992, 86, 134-138.	1.0	52
6	Switching from natalizumab to fingolimod: an observational study. Acta Neurologica Scandinavica, 2013, 128, e6-e10.	1.0	52
7	Rebound of disease activity during pregnancy after withdrawal of fingolimod. European Journal of Neurology, 2013, 20, e109-10.	1.7	52
8	Acute Headache of Recent Onset and Subarachnoid Hemorrhage: A Prospective Study. Headache, 1994, 34, 172-174.	1.8	45
9	Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS). Frontiers in Neurology, 2017, 8, 65.	1.1	42
10	Incidence of Transient Ischemic Attacks and Minor Ischemic Strokes in Segovia, Spain. Stroke, 1996, 27, 667-671.	1.0	42
11	Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS). BMC Neurology, 2016, 16, 58.	0.8	41
12	Spongiform leucoencephalopathy after inhaling heroin. Lancet, The, 1991, 338, 320.	6.3	35
13	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	1.4	35
14	Cerebral Ischemia: New Risk Factors. Cerebrovascular Diseases, 2004, 17, 43-50.	0.8	32
15	Headache of recent onset in adults: a prospective population-based study. Acta Neurologica Scandinavica, 1996, 94, 67-70.	1.0	29
16	Mutation Prevalence of Cerebral Cavernous Malformation Genes in Spanish Patients. PLoS ONE, 2014, 9, e86286.	1.1	29
17	Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open, 2017, 7, e014433.	0.8	28
18	Parkinsonism induced by amlodipine. Movement Disorders, 1995, 10, 115-116.	2.2	27

ANGEL PEREZ-SEMPERE

#	Article	IF	CITATIONS
19	SARS-CoV-2 Infection in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	27
20	Response to Immunotherapy in CLIPPERS: Clinical, MRI, and MRS Followâ€Up. Journal of Neuroimaging, 2013, 23, 254-255.	1.0	26
21	Aggravation of Parkinsonian Tremor by Cisapride. Clinical Neuropharmacology, 1995, 18, 76-78.	0.2	24
22	Etiopathogenesis of Transient Ischemic Attacks and Minor Ischemic Strokes. Stroke, 1998, 29, 40-45.	1.0	24
23	Bibliometric profile of the global scientific research on multiple sclerosis (2003–2012). Multiple Sclerosis Journal, 2015, 21, 235-245.	1.4	24
24	Realâ€world experience of ocrelizumab in multiple sclerosis in a Spanish population. Annals of Clinical and Translational Neurology, 2021, 8, 385-394.	1.7	23
25	Isolated idiopathic adult-onset foot dystonia and treatment with botulinum toxin. Journal of Neurology, 1995, 242, 114-115.	1.8	19
26	Primary Cough Headache Responsive to Topiramate. Cephalalgia, 2005, 25, 627-628.	1.8	18
27	Capture-Recapture as a Potentially Useful Procedure for Assessing Prevalence of Multiple Sclerosis: Methodologic Exercise Using Portuguese Data. Neuroepidemiology, 2012, 38, 209-216.	1.1	18
28	Postural Myoclonus Induced by Phenytoin. Clinical Neuropharmacology, 1996, 19, 536-538.	0.2	17
29	Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. Journal of Neurology, 2019, 266, 2512-2517.	1.8	17
30	Clinical characteristics associated with psychosocial functioning among patients with uncomplicated epilepsy in Spain. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 195-203.	0.9	16
31	Rescue Therapy Using Rituximab for Multiple Sclerosis. Clinical Neuropharmacology, 2016, 39, 178-181.	0.2	16
32	Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. Frontiers in Neurology, 2017, 8, 430.	1.1	16
33	Parkinsonism and tardive dyskinesia after chronic use of clebopride. Movement Disorders, 1994, 9, 114-115.	2.2	14
34	Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1338-1339.	0.9	14
35	Pseudopheochromocytoma in a Patient with Parkinson's Disease. Annals of Pharmacotherapy, 1996, 30, 546-546.	0.9	13
36	Observational Study of Switching from Natalizumab to Immunomodulatory Drugs. European Neurology, 2017, 77, 130-136.	0.6	13

ANGEL PEREZ-SEMPERE

#	Article	IF	CITATIONS
37	Isolated Oculomotor Nerve Palsy due to Dural Cavernous Sinus Fistula. European Neurology, 1991, 31, 186-187.	0.6	12
38	Low-Dose Sodium Valproate in the Prophylaxis of Migraine. Clinical Neuropharmacology, 1994, 17, 569-573.	0.2	12
39	Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MS. Patient Preference and Adherence, 2017, Volume 11, 175-180.	0.8	11
40	Guillain-Barr6 Syndrome After Acute Myocardial Infarction Treated With Anistreplase. Chest, 1994, 105, 1301-1302.	0.4	10
41	Bilateral optic neuritis in a 26-year-old man with common variable immunodeficiency: a case report. Journal of Medical Case Reports, 2011, 5, 319.	0.4	9
42	Benign hereditary chorea: Clinical features and long-term follow-up in a Spanish family. Parkinsonism and Related Disorders, 2013, 19, 394-396.	1.1	9
43	Eyelid myokymia in patients with migraine taking topiramate. Acta Neurologica Scandinavica, 2015, 132, 143-146.	1.0	9
44	Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient's Perspective. Neurology and Therapy, 2020, 9, 173-179.	1.4	9
45	Reversible Dementia Secondary to Topiramate. Clinical Neuropharmacology, 2008, 31, 62.	0.2	8
46	Multiple sclerosis prevalence and incidence in San Vicente del Raspeig, Spain. Multiple Sclerosis and Related Disorders, 2019, 33, 78-81.	0.9	8
47	Understanding the Deterioration of Gait, Postural Control, Lower Limb Strength and Perceived Fatigue Across the Disability Spectrum of People with Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 1385.	1.0	7
48	Safety considerations when choosing the appropriate treatment for patients with multiple sclerosis. Expert Opinion on Drug Safety, 2014, 13, 1287-1289.	1.0	6
49	Intravenous Midazolam Suppression of Complex Partial Status Refractory to Intravenous Phenytoin and Diazepam. Clinical Neuropharmacology, 1993, 16, 468-470.	0.2	5
50	Linfoma cerebral primario con remisión espontánea. NeurologÃa, 2013, 28, 123-126.	0.3	5
51	Folletos de información educativa en migraña: satisfacción percibida en un grupode pacientes. NeurologÃa, 2015, 30, 472-478.	0.3	5
52	Contribution of Gray Matter Atrophy and White Matter Damage to Cognitive Impairment in Mildly Disabled Relapsing-Remitting Multiple Sclerosis Patients. Diagnostics, 2021, 11, 578.	1.3	5
53	Regret and Therapeutic Decisions in Multiple Sclerosis Care: Literature Review and Research Protocol. Frontiers in Neurology, 2021, 12, 675520.	1.1	5
54	Bilateral akinetic seizures: A clinical and electroencephalographic description. Epilepsia, 2010, 51, 2108-2115.	2.6	4

#	Article	IF	CITATIONS
55	Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: A sign of poor self-perception of their clinical status?. Multiple Sclerosis and Related Disorders, 2020, 45, 102354.	0.9	4
56	Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain. PLoS ONE, 2021, 16, e0261050.	1.1	4
57	Serum levels of nitrates in focal cerebral ischemia. European Journal of Neurology, 1995, 2, 225-227.	1.7	3
58	Generalized spike-and-wave patterns in children: clinical correlates. Pediatric Neurology, 2000, 22, 23-28.	1.0	3
59	Oral BG-12 in Multiple Sclerosis. New England Journal of Medicine, 2013, 368, 1652-1653.	13.9	3
60	Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731983522.	0.5	3
61	Cerebral venous thrombosis as a cause of neonatal focal clonic seizures. Journal of Neurology, 1992, 239, 294-294.	1.8	3
62	Impotence Associated with Cinnarizine. Annals of Pharmacotherapy, 1993, 27, 370-371.	0.9	2
63	Peripheral iron metabolism in patients with focal cerebral ischemia. European Journal of Neurology, 1995, 2, 107-109.	1.7	2
64	Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 1996, 3, 397-398.	1.7	2
65	A general presentation on how to carry out a <scp>CHARMS</scp> analysis for prognostic multivariate models. Statistics in Medicine, 2020, 39, 3207-3225.	0.8	2
66	High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions. Patient, 2021, 14, 241-248.	1.1	2
67	Thyroxine-Induced Partial Complex Status Epilepticus. Annals of Pharmacotherapy, 1993, 27, 1139-1139.	0.9	1
68	Efficacy of Intranasal Apomorphine in Parkinson's Disease. Journal of Pharmacy Technology, 1995, 11, 226-228.	0.5	1
69	Adaptación cultural y validación al español de España del MSTCQ© (Multiple Sclerosis Treatment) Tj ETQq1	1 0.7843 0.3	314 rgBT /O

70Non-ischaemic causes of transient ischaemic attacks and minor strokes.. Journal of Neurology,
Neurosurgery and Psychiatry, 1994, 57, 659-660.0.90